Overview
To evaluate the safety and initial efficacy of STSA-1002 injection in patients with acute respiratory distress syndrome.
Eligibility
Inclusion Criteria:
- 18 years old≤Age≤85 years old;
- In 14 days since the onset of respiratory infective symptoms (in 12 days for non-invasive mechanical ventilation patients);
- The nearest PaO2/FiO2≤200mmHg;
- Low peripheral blood lymphocyte count;
- Patients (including patients' partners) did not plan to have children during the trial period and for 4 months after the end of the last dose and agreed to use appropriate and effective contraceptive methods;
Exclusion Criteria:
- Use ECMO before first administration;
- The time between first administration and invasive mechanical ventilation was more than 48h;
- Survival is expected to be no more than 24 hours or a cardiac arrest has occurred 4 weeks before screening;
- Vital organs failure, including the liver, kidneys and heart;
- Immunosuppressed state;
- Serious underlying disease.